These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3976729)

  • 1. In vivo alteration of a mutant human protein using the free thiol cysteamine.
    Gahl WA; Gregg RE; Hoeg JM; Fisher E
    Am J Med Genet; 1985 Feb; 20(2):409-17. PubMed ID: 3976729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel electrophoretic variant of human apolipoprotein E. Identification and characterization of apolipoprotein E1.
    Weisgraber KH; Rall SC; Innerarity TL; Mahley RW; Kuusi T; Ehnholm C
    J Clin Invest; 1984 Apr; 73(4):1024-33. PubMed ID: 6323533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia.
    Wardell MR; Brennan SO; Janus ED; Fraser R; Carrell RW
    J Clin Invest; 1987 Aug; 80(2):483-90. PubMed ID: 3038959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein E Bethesda. Isolation and partial characterization of a variant of human apolipoprotein E isolated from very low density lipoproteins.
    Ghiselli G; Gregg RE; Brewer HB
    Biochim Biophys Acta; 1984 Jul; 794(2):333-9. PubMed ID: 6428460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a new structural variant of human apolipoprotein E, E2(Lys146 leads to Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype.
    Rall SC; Weisgraber KH; Innerarity TL; Bersot TP; Mahley RW; Blum CB
    J Clin Invest; 1983 Oct; 72(4):1288-97. PubMed ID: 6313758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cysteamine in the treatment of cystinosis in children. In vitro and in vivo studies].
    Louis JJ; Guibaud P; Dumoulin R; Parchoux B; Zabot MT; Bureau J; Baltassat P; Frederich A; Larbre F
    Pediatrie; 1984 Dec; 39(8):619-33. PubMed ID: 6535971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation.
    Innerarity TL; Weisgraber KH; Arnold KS; Rall SC; Mahley RW
    J Biol Chem; 1984 Jun; 259(11):7261-7. PubMed ID: 6327714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of cystinosis using cysteamine].
    Broyer M; Tete MJ
    Ann Pediatr (Paris); 1990 Feb; 37(2):91-3. PubMed ID: 2321906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type III hyperlipoproteinemia with xanthomas and multiple myeloma.
    Burnside NJ; Alberta L; Robinson-Bostom L; Bostom A
    J Am Acad Dermatol; 2005 Nov; 53(5 Suppl 1):S281-4. PubMed ID: 16227109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of variant apolipoprotein E by isoelectric focusing and restriction isotyping in a patient with type III hyperlipoproteinemia.
    Nassar BA; McPherson R; Lamothe EM; al-Sultan AI; Zhang ZJ; Rosenblatt DS
    Clin Chem; 1991 Jul; 37(7):1308. PubMed ID: 1677318
    [No Abstract]   [Full Text] [Related]  

  • 11. [Intra-leukocyte cystine in cystinosis treated with cysteamine].
    Ged C; Jean G; Tete MJ; Broyer M; Kamoun P
    Ann Biol Clin (Paris); 1991; 49(9):482-6. PubMed ID: 1789502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized clinical trial of topical cysteamine disulfide (cystamine) versus free thiol (cysteamine) in the treatment of corneal cystine crystals in cystinosis.
    Iwata F; Kuehl EM; Reed GF; McCain LM; Gahl WA; Kaiser-Kupfer MI
    Mol Genet Metab; 1998 Aug; 64(4):237-42. PubMed ID: 9758713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephropathic cystinosis: effect of long-term cysteamine therapy.
    Proesmans W; Baten E; Hoogmartens J; Bruyneel P
    Clin Nephrol; 1987 Jun; 27(6):309-12. PubMed ID: 3608256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restriction isotyping of apolipoprotein E R145C in type III hyperlipoproteinemia.
    Hsia SH; Connelly PW; Hegele RA
    J Investig Med; 1995 Apr; 43(2):187-94. PubMed ID: 7735921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New mutants of apolipoprotein E associated with atherosclerotic diseases but not to type III hyperlipoproteinemia.
    Yamamura T; Yamamoto A; Sumiyoshi T; Hiramori K; Nishioeda Y; Nambu S
    J Clin Invest; 1984 Oct; 74(4):1229-37. PubMed ID: 6480826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The structure of human apolipoprotein E2, E3 and E4 in solution. 2. Multidomain organization correlates with the stability of apoE structure.
    Clément-Collin V; Barbier A; Dergunov AD; Visvikis A; Siest G; Desmadril M; Takahashi M; Aggerbeck LP
    Biophys Chem; 2006 Jan; 119(2):170-85. PubMed ID: 16125836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of cystinosis with cysteamine. A pilot study determining dose and form of application.
    Bergonzi E; Herren A; Lavanchy P; Bühlmann C; Wyss SR; Lüthy C; Oetliker O
    Helv Paediatr Acta; 1981 Nov; 36(5):437-43. PubMed ID: 7031022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Apolipoprotein E phenotyping--useful in the study of hyperlipoproteinemia type III].
    Hagve TA; Furuset T; Christophersen B; Ose L
    Tidsskr Nor Laegeforen; 1993 Mar; 113(7):853-6. PubMed ID: 8480294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease.
    Aleshkov S; Abraham CR; Zannis VI
    Biochemistry; 1997 Aug; 36(34):10571-80. PubMed ID: 9265639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unusual xanthomas in a young patient with heterozygous familial hypercholesterolemia and type III hyperlipoproteinemia.
    Feussner G; Dobmeyer J; Nissen H; Hansen TS
    Am J Med Genet; 1996 Oct; 65(2):149-54. PubMed ID: 8911609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.